Apollomics (NASDAQ:APLM) Shares Gap Down – Should You Sell?

Apollomics, Inc. (NASDAQ:APLM)’s share price gapped down before the market opened on Monday . The stock had previously closed at $9.18, but opened at $8.40. Apollomics shares last traded at $8.47, with a volume of 14,344 shares.

Apollomics Trading Up 5.7 %

The firm has a fifty day moving average price of $13.21 and a 200-day moving average price of $17.89.

Institutional Investors Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation boosted its stake in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the period. Apollomics makes up approximately 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th biggest holding. George Kaiser Family Foundation owned approximately 0.75% of Apollomics worth $141,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.